This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
12 Jan 2017

Sartorius Stedim Biotech opens a new validation service laboratory at its Shanghai site

Opening of Sartorius Stedim Biotech’s new validation service laboratory in Shanghai: Dr. Jörg Lindenblatt, SSB’s Senior Vice President of Sales for Bioprocess Solutions in Asia (4th from left), joined by business partners and colleagues in cutting the ribbon.

Comprehensive validation services for the Chinese market.

Sartorius Stedim Biotech (SSB) has opened a new validation service laboratory yesterday at its site in Shanghai Zhangjiang Hi-Tech Park. The opening event was attended by business partners from the biopharmaceutical industry and representatives of the local community.

With its new laboratory, SSB is making validation of membrane filters even more convenient and time-saving. Chinese customers can have their entire process steps validated locally and will also benefit from direct interaction with Sartorius specialists on site.

“Our Shanghai validation lab provides high-quality services that are fully compliant with applicable GMP and GLP principles. At this validation service lab, we now offer comprehensive process validation studies for the strongly growing Chinese pharma market,” stated Dr Jörg Lindenblatt, SSB’s Senior Vice President of Sales for Bioprocess Solutions in Asia, in his opening speech. The validation lab, together with SSB’s Application Center in Shanghai, provides a full range of extended services to the biopharmaceutical industry.

SSB’s new Shanghai laboratory covers approximately 4,000 sq ft (370 m2). Equipped with the latest instrumentation, it offers microbiological testing services and physical-chemical testing to provide a full range of data for process validation studies in compliance with all regulatory requirements. Certified according to Biosafety Level II (BSL-2), the facility is permitted to handle specific critical bacteria and customer products.

Related News

  • News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel

    A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to...
  • News Protecting life-saving therapies: CPHI Online Podcast Series

    The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.

  • News 2026 Outsourcing Outlook Update - pharma at a crossroads

    The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ...
  • News Roche maintains German investment commitment whilst rivals scale back

    Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.

  • News Women in Pharma: The History of CPHI Women in Japan

    Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive.
  • News EU drafts deal to end essential medicines shortage

    European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.

  • News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg

    The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th...
  • News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026

    CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.